Switzerland's 4-Antibody AG has rounded up 17 million Swiss Francs ($18.5 million) in its first round of development. The developer plans to use the money advance new antibodies. The U.K.'s Advent Venture Partners led the round, which was announced on Monday.
"The success of our Series A financing is a recognition of the potential of our proprietary 4mAb(TM) platform to generate novel fully human antibodies against a broad range of disease targets," said Sijmen de Vries, CEO of 4-Antibody AG.
- here's the release for more information